Dr. Liliane Massade, INSERM, France.
Dr. Liliane Massade is a visionary research leader whose work integrates molecular biology, nanotechnology, and translational medicine. From her academic roots in Lebanon to her pioneering research in France, she has achieved significant milestones, including the development of siRNA-based therapies for Charcot-Marie-Tooth disease and innovations in neurodegenerative and cancer treatments. Her career spans decades of groundbreaking discoveries, interdisciplinary collaborations, and impactful mentorship. With over 78 publications, patents, and numerous awards, Dr. Massade’s contributions are both scientifically profound and globally influential.
Profile
Orcid
🌟 Early Academic Pursuits
Dr. Liliane Massade’s academic journey began with her passion for biology and education. After earning her Master’s in Biology from Lebanese University in 1982, she followed her calling as a teacher, obtaining a Teaching Diploma from Ecole Normale, Lebanon, in 1981. Her thirst for knowledge led her to Paris Diderot University, where she completed an Advanced Studies Diploma (DEA) in Population Genetics and Evolution in 1986. By 1990, she had earned her Ph.D. in Population Genetics and Evolution, marking the start of her illustrious career. In 1996, she achieved the Authorization to Supervise Research (HDR), solidifying her role as a mentor and leader in her field.
🔬 Professional Endeavors
Dr. Massade’s career has been a symphony of innovation, leadership, and groundbreaking research. Since 2020, she has led a cutting-edge team at U1195 INSERM, Bicêtre University Hospital, focusing on targeted therapies for chemotherapy-induced peripheral neuropathies. Prior to this, she helmed teams at UMR 8203 CNRS, Gustave Roussy Institute, where she advanced anti-cancer therapies and explored molecular targets in thyroid cancer. Her earlier work at INSERM and CNRS saw her delve into estradiol signaling in breast cancer and enzymes in drug metabolism, laying the foundation for her expertise in molecular biology and translational medicine.
💡 Contributions and Research Focus
Dr. Massade’s pioneering spirit has transformed the fields of neurodegenerative diseases and oncology. She is celebrated for her groundbreaking siRNA-based therapies targeting PMP22, which have opened new horizons for Charcot-Marie-Tooth disease treatment. Her innovations extend beyond therapy, as her patented methods in nucleic acid transfer highlight her interdisciplinary approach. With a focus on integrating biology, chemistry, and nanotechnology, she leads research that merges fundamental science with clinical application, offering hope for conditions like peripheral neuropathy and neurodegeneration.
🏆 Accolades and Recognition
Throughout her career, Dr. Massade has earned prestigious accolades, including the Outstanding Achievement Award at the World Congress on Advances in Oncology in 2013 and the JW Griffin Prize for Regeneration from the Peripheral Nerve Society in 2021. Her impact is further underscored by her extensive publication record, with 78 works, an H-index of 26, and over 49 invited talks at international conferences. These honors reflect her global influence and her ability to inspire the next generation of researchers.
🌍 Impact and Influence
Dr. Massade’s contributions extend beyond her lab, as she evaluates research programs for renowned organizations like the ERC, ANR, and ARC. As a member of international committees such as LaBEX NanoSaclay, she ensures the advancement of cutting-edge nanotechnology. Her mentorship has shaped the careers of 10 postdoctoral researchers, 11 Ph.D. candidates, and 31 Master’s students, demonstrating her commitment to nurturing scientific talent.
🔗 Legacy and Future Contributions
As the co-founder of MAAsiRNA, Dr. Massade exemplifies the translation of research into real-world impact. With €7 million raised to develop therapies targeting PMP22, her work bridges the gap between science and patient care. Her vision for the future includes continued exploration of siRNA therapies and the development of innovative approaches to neuroprotection and cancer treatment. Her legacy is one of scientific excellence, interdisciplinary collaboration, and unwavering dedication to improving lives through research.
📚Publications
- GRT-X Stimulates Dorsal Root Ganglia Axonal Growth in Culture via TSPO and Kv7.2/3 Potassium Channel Activation
Authors: Léa El Chemali, Suzan Boutary, Song Liu, Guo-Jun Liu, Ryan J. Middleton, Richard B. Banati, Gregor Bahrenberg, Rainer Rupprecht, Michael Schumacher, Liliane Massaad-Massade
Year: 2024
- Optimizing Structure and Activity of the Squalenoyl-siRNA Nanoparticles
Author: Liliane Massaad-Massade
Year: 2023
- Mutation of Proteolipid Protein 1 Gene: From Severe Hypomyelinating Leukodystrophy to Inherited Spastic Paraplegia
Authors: Guy Khalaf, Claudia Mattern, Mélina Begou, Odile Boespflug-Tanguy, Charbel Massaad, Liliane Massaad-Massade
Year: 2022
- The Mitochondrial Translocator Protein (TSPO): A Key Multifunctional Molecule in the Nervous System
Authors: Léa El Chemali, Yvette Akwa, Liliane Massaad-Massade
Year: 2022
- Supramolecular Organization and Biological Interaction of Squalenoyl siRNA Nanoparticles
Authors: Marie Caillaud, Frédéric Gobeaux, Miryana Hémadi, Suzan Boutary, Patrick Guenoun, Didier Desmaële, Patrick Couvreur, Frank Wien, Fabienne Testard, Liliane Massaad-Massade
Year: 2021
- Squalenoyl siRNA PMP22 Nanoparticles Are Effective in Treating Mouse Models of Charcot-Marie-Tooth Disease Type 1A
Author: Liliane Massaad-Massade
Year: 2021
- Treating PMP22 Gene Duplication-Related Charcot-Marie-Tooth Disease: The Past, the Present, and the Future
Author: Liliane Massaad-Massade
Year: 2020
- Small Interfering RNA From the Lab Discovery to Patients’ Recovery
Authors: Marie Caillaud, Mévidette El Madani, Liliane Massaad-Massade
Year: 2020
- Newly Identified LMO3-BORCS5 Fusion Oncogene in Ewing Sarcoma at Relapse Is a Driver of Tumor Progression
Author: Liliane Massaad-Massade
Year: 2019
- A Novel Therapeutic Approach to Colorectal Cancer in Diabetes: Role of Metformin and Rapamycin
Author: Liliane Massaad-Massade
Year: 2019
- Discovery of New Fusion Transcripts in a Cohort of Pediatric Solid Cancers at Relapse and Relevance for Personalized Medicine
Author: Liliane Massaad-Massade
Year: 2019
🌟 Conclusion
Dr. Liliane Massade is a beacon of innovation and leadership in molecular biology and targeted therapies. From her academic beginnings in Lebanon to her groundbreaking contributions in France, she has forged a path of excellence that inspires scientists worldwide. With her unparalleled expertise and passion, she continues to redefine the possibilities of modern medicine, leaving an indelible mark on science and humanity.